Emerging Treatment from novel targets for Alzheimer Disease

Author : Inderpal Kaur, Chetna Sharma and Aashish Sharma

Alzheimer disease (AD) is a neuropathological disease involving progressive neurodegeneration, initially impacting memory, and leading to progressive and irreversible cognitive decline and functional impairment. Tacrine was the first centrally acting cholinesterase drug discovered but was withdrawn because of hepatotoxicity. Currently there are four drugs being used for the treatment which includes donepezil, galantamine, rivastigmine, and memantine. The numerous complex and interrelated biochemical pathways underlying neurodegeneration in Alzheimer’s disease provide numerous potential targets for therapeutic interventions. This review article is based on the various research findings done during the past two decades and will certainly help research scholar’s to do further research in this field and will help in the development of drugs that will improve the quality of life of patients and will decrease care giver burden.

Full Text Attachment

Creative Commons License World Journal of Pharmaceutical Science is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at Permissions beyond the scope of this license may be available at